Chakrapol Sriaroon, MD
Pulmonary Disease · Tampa, FLNPI 1275728313
Payments from drug & device makers
Across 388 payments — averaging $919.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$188K
- Insmed, Inc.$140K
- Mannkind Corporation$27K
- United Therapeutics Corporation$449
- Penumbra, Inc.$174
- Innovation Technologies Inc$174
- plus $1K from 16 others
Across 9 payments — averaging $304.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Paratek Pharmaceuticals, Inc.$1K
- Insmed, Inc.$1K
What the payments were for
- Consulting fees$20,69132%
- Speaking & faculty fees$34,32353%
- Travel & lodging$4,2807%
- Food & beverage$5,2398%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 76 | $187,662 |
| Insmed, Inc. | 276 | $140,178 |
| Mannkind Corporation | 6 | $26,923 |
| United Therapeutics Corporation | 6 | $449 |
| Penumbra, Inc. | 1 | $174 |
| Innovation Technologies Inc | 1 | $174 |
| Shionogi Inc | 4 | $159 |
| Astellas Pharma US Inc | 1 | $131 |
| Abiomed | 1 | $130 |
| La Jolla Pharmaceutical Company | 2 | $126 |
| Boehringer Ingelheim | 1 | $125 |
| AbbVie | 1 | $120 |
| Viatris Specialty LLC | 1 | $98 |
| AstraZeneca | 1 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $75 |
| Mylan Specialty L.p. | 3 | $66 |
| Pulmonx Corporation | 1 | $27 |
| Medtronic | 1 | $25 |
| Vertex | 1 | $22 |
| Invivyd Inc | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$356,814 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 324 | $8,070,877 |
| CreonLipase/Protease/Amylase | 91 | $475,698 |
| CaystonAztreonam Lysine | 22 | $266,491 |
| ZenpepLipase/Protease/Amylase | 37 | $226,949 |
| Tobi PodhalerTobramycin | 20 | $209,431 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $25,235 |
| Spiriva HandihalerTiotropium Bromide | 18 | $16,217 |
| Spiriva RespimatTiotropium Bromide | 16 | $15,249 |
| LinzessLinaclotide | 22 | $14,118 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,541 |
| MotegrityPrucalopride Succinate | 11 | $5,741 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,443 |
| Ventolin HfaAlbuterol Sulfate | 67 | $4,390 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,074 |
| Azithromycin | 157 | $3,930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $22 | $8,070,877324 claims |
| AbbVieCreon, Linzess | $120 | $489,816113 claims |
| Mylan Specialty L.p.Tobi Podhaler | $66 | $209,43120 claims |
| Boehringer IngelheimSpiriva Respimat | $125 | $15,24916 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $75 | $5,74111 claims |
| AstraZenecaSymbicort | $93 | $4,44318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Tampa
- Ricardo Restrepo-JaramilloTampa$2.9M
- Rafael MartinezTampa$917K
- Karel CaleroTampa$542K
- Mark RumbakTampa$528K
- Domenick ReinaTampa$469K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.